Logo image of AYTU

AYTU BIOPHARMA INC (AYTU) Stock Fundamental Analysis

USA - NASDAQ:AYTU - US0547548588 - Common Stock

1.8494 USD
-0.21 (-10.22%)
Last: 9/25/2025, 2:51:08 PM
Fundamental Rating

3

AYTU gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 196 industry peers in the Pharmaceuticals industry. AYTU has a medium profitability rating, but doesn't score so well on its financial health evaluation. AYTU is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

4

1. Profitability

1.1 Basic Checks

AYTU had positive earnings in the past year.
AYTU had a negative operating cash flow in the past year.
In the past 5 years AYTU always reported negative net income.
AYTU had a negative operating cash flow in each of the past 5 years.
AYTU Yearly Net Income VS EBIT VS OCF VS FCFAYTU Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M -80M -100M

1.2 Ratios

Looking at the Return On Assets, with a value of 1.32%, AYTU belongs to the top of the industry, outperforming 82.14% of the companies in the same industry.
The Return On Equity of AYTU (4.70%) is better than 84.18% of its industry peers.
AYTU's Return On Invested Capital of 0.46% is fine compared to the rest of the industry. AYTU outperforms 77.55% of its industry peers.
Industry RankSector Rank
ROA 1.32%
ROE 4.7%
ROIC 0.46%
ROA(3y)-35%
ROA(5y)-27.17%
ROE(3y)-112.19%
ROE(5y)-78.65%
ROIC(3y)N/A
ROIC(5y)N/A
AYTU Yearly ROA, ROE, ROICAYTU Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -100 -200 -300 -400 -500

1.3 Margins

Looking at the Profit Margin, with a value of 2.37%, AYTU belongs to the top of the industry, outperforming 81.12% of the companies in the same industry.
AYTU's Operating Margin of 0.53% is fine compared to the rest of the industry. AYTU outperforms 77.55% of its industry peers.
With a decent Gross Margin value of 68.59%, AYTU is doing good in the industry, outperforming 76.53% of the companies in the same industry.
AYTU's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 0.53%
PM (TTM) 2.37%
GM 68.59%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y14.82%
GM growth 5Y-0.72%
AYTU Yearly Profit, Operating, Gross MarginsAYTU Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -500 -1K -1.5K -2K -2.5K

More info and screens

1

2. Health

2.1 Basic Checks

AYTU has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
There is no outstanding debt for AYTU. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
AYTU Yearly Shares OutstandingAYTU Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 1M 2M 3M 4M 5M
AYTU Yearly Total Debt VS Total AssetsAYTU Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

2.2 Solvency

Based on the Altman-Z score of -2.83, we must say that AYTU is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of AYTU (-2.83) is comparable to the rest of the industry.
A Debt/Equity ratio of 0.56 indicates that AYTU is somewhat dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.56, AYTU is doing worse than 62.24% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.56
Debt/FCF N/A
Altman-Z -2.83
ROIC/WACC0.03
WACC16.66%
AYTU Yearly LT Debt VS Equity VS FCFAYTU Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M 100M

2.3 Liquidity

AYTU has a Current Ratio of 1.03. This is a normal value and indicates that AYTU is financially healthy and should not expect problems in meeting its short term obligations.
AYTU has a Current ratio of 1.03. This is amonst the worse of the industry: AYTU underperforms 80.10% of its industry peers.
AYTU has a Quick Ratio of 1.03. This is a bad value and indicates that AYTU is not financially healthy enough and could expect problems in meeting its short term obligations.
With a Quick ratio value of 0.87, AYTU is not doing good in the industry: 78.06% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 1.03
Quick Ratio 0.87
AYTU Yearly Current Assets VS Current LiabilitesAYTU Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

More info and screens

4

3. Growth

3.1 Past

AYTU shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 104.55%, which is quite impressive.
EPS 1Y (TTM)104.55%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%68.29%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-15.78%

3.2 Future

The Earnings Per Share is expected to grow by 127.56% on average over the next years. This is a very strong growth
AYTU is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 14.87% yearly.
EPS Next Y-766.92%
EPS Next 2Y127.56%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year2%
Revenue Next 2Y19.63%
Revenue Next 3Y21.27%
Revenue Next 5Y14.87%

3.3 Evolution

AYTU Yearly Revenue VS EstimatesAYTU Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 50M 100M
AYTU Yearly EPS VS EstimatesAYTU Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2019 2020 2021 2022 2023 2024 2025 2026 2027 0 -50K -100K -150K

More info and screens

3

4. Valuation

4.1 Price/Earnings Ratio

AYTU is valuated correctly with a Price/Earnings ratio of 14.23.
Based on the Price/Earnings ratio, AYTU is valued cheaper than 84.69% of the companies in the same industry.
AYTU's Price/Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 27.29.
The Forward Price/Earnings Ratio is negative for AYTU. No positive earnings are expected for the next year.
Industry RankSector Rank
PE 14.23
Fwd PE N/A
AYTU Price Earnings VS Forward Price EarningsAYTU Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 5 10 15 20 25

4.2 Price Multiples

100.00% of the companies in the same industry are more expensive than AYTU, based on the Enterprise Value to EBITDA ratio.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 1.83
AYTU Per share dataAYTU EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4 6

4.3 Compensation for Growth

AYTU's earnings are expected to grow with 127.56% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y127.56%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for AYTU!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

AYTU BIOPHARMA INC

NASDAQ:AYTU (9/25/2025, 2:51:08 PM)

1.8494

-0.21 (-10.22%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)09-23 2025-09-23/amc
Earnings (Next)11-11 2025-11-11
Inst Owners27.72%
Inst Owner Change80.96%
Ins Owners8.18%
Ins Owner Change0.54%
Market Cap16.61M
Analysts82.22
Price Target9.86 (433.15%)
Short Float %5.66%
Short Ratio3.96
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)115.04%
Min EPS beat(2)8.96%
Max EPS beat(2)221.11%
EPS beat(4)3
Avg EPS beat(4)94.57%
Min EPS beat(4)-78.65%
Max EPS beat(4)226.87%
EPS beat(8)6
Avg EPS beat(8)-375.67%
EPS beat(12)8
Avg EPS beat(12)-262.38%
EPS beat(16)9
Avg EPS beat(16)-226.19%
Revenue beat(2)2
Avg Revenue beat(2)16.96%
Min Revenue beat(2)2.24%
Max Revenue beat(2)31.67%
Revenue beat(4)3
Avg Revenue beat(4)11.43%
Min Revenue beat(4)-3.7%
Max Revenue beat(4)31.67%
Revenue beat(8)6
Avg Revenue beat(8)4.72%
Revenue beat(12)8
Avg Revenue beat(12)2.67%
Revenue beat(16)9
Avg Revenue beat(16)1.15%
PT rev (1m)13.73%
PT rev (3m)7.41%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-106.92%
EPS NY rev (1m)0%
EPS NY rev (3m)-15.97%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-8.59%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-2.4%
Valuation
Industry RankSector Rank
PE 14.23
Fwd PE N/A
P/S 0.24
P/FCF N/A
P/OCF N/A
P/B 0.48
P/tB N/A
EV/EBITDA 1.83
EPS(TTM)0.13
EY7.03%
EPS(NY)-0.87
Fwd EYN/A
FCF(TTM)-0.64
FCFYN/A
OCF(TTM)-0.62
OCFYN/A
SpS7.71
BVpS3.89
TBVpS-1.54
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 1.32%
ROE 4.7%
ROCE 0.69%
ROIC 0.46%
ROICexc 0.64%
ROICexgc N/A
OM 0.53%
PM (TTM) 2.37%
GM 68.59%
FCFM N/A
ROA(3y)-35%
ROA(5y)-27.17%
ROE(3y)-112.19%
ROE(5y)-78.65%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y14.82%
GM growth 5Y-0.72%
F-Score4
Asset Turnover0.56
Health
Industry RankSector Rank
Debt/Equity 0.56
Debt/FCF N/A
Debt/EBITDA 3.06
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage 0.13
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.03
Quick Ratio 0.87
Altman-Z -2.83
F-Score4
WACC16.66%
ROIC/WACC0.03
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)104.55%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%68.29%
EPS Next Y-766.92%
EPS Next 2Y127.56%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-15.78%
Revenue Next Year2%
Revenue Next 2Y19.63%
Revenue Next 3Y21.27%
Revenue Next 5Y14.87%
EBIT growth 1Y-80.87%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year402.12%
EBIT Next 3Y131.97%
EBIT Next 5Y106.24%
FCF growth 1Y73.41%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y74.38%
OCF growth 3YN/A
OCF growth 5YN/A